许培扬博客分享 http://blog.sciencenet.cn/u/xupeiyang 跟踪国际前沿 服务国内科研

博文

埃博拉临床试验信息分析(21项)

已有 2222 次阅读 2014-11-27 14:17 |个人分类:信息分析|系统分类:科研笔记

 

埃博拉临床试验信息分析(21项)

地区、国家分布

 

Region Name  Number of Studies
World21 
Africa   [map]  3 
Europe   [map]  4 
North America12 
United States   [map]  12  [studies]
Found 21 studies with search of:  EBOLA
研究内容和主题分布
Related Terms:
Click on a related term to refine your search.
This will narrow your search by adding an additional search term.
If your search becomes too narrow (finds too few studies), broaden it by removing search terms with the Refine Search page.

EEbola Virus
Ebola Virus Disease
Ebola vaccine
HHealthy Adult
Hemorrhagic
Hemorrhagic Fevers
Hemorrhagic Fever, Ebola
IInfections
PPhase 1
VVirus
Ebola Virus
Ebola Virus Disease
Virus Diseases
Ebola Virus Disease
Volunteers
ZZaire
Ffever
Hemorrhagic Fevers
Hemorrhagic Fever, Ebola
Vvaccine
Ebola vaccine

 

 

21 studies found for:    EBOLA
Include only open studies Exclude studies with unknown status
RankStatusStudy
1CompletedEvaluating an Ebola and a Marburg Vaccine in Uganda
Conditions:Ebola Virus Disease;   Marburg Virus Disease
Interventions:Biological: Ebola vaccine;   Biological: Marburg vaccine;   Other: Placebo injection
2RecruitingPhase 1 Trial of Ebola Vaccine in Mali
Conditions:Ebola Virus Disease;   Hemorrhagic Fever
Intervention:Biological: Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z)
3Active, not recruitingA Study to Assess a New Ebola Vaccine, cAd3-EBO Z
Conditions:Ebola;   Ebola Zaire
Interventions:Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp
4CompletedExperimental Vaccine for Prevention of Ebola Virus Infection
Conditions:Ebola Hemorrhagic Fever;   Ebola Virus Disease;   Ebola Virus Vaccines;   Envelope Glycoprotein, Ebola Virus;   Filovirus
Intervention:Drug: VRC-EBOADV018-00-VP
5RecruitingPhase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)
Condition:Hemorrhagic Fever, Ebola
Intervention:Biological: rVSVΔ-ZEBOV-GP
6CompletedEbola and Marburg Virus Vaccines
Conditions:Ebola Vaccines;   Marburg Virus Disease;   Ebola Virus Disease;   Marburgvirus;   Ebolavirus
Interventions:Drug: VRC-EBODNA023-00-VP;   Drug: VRC-MARDNA025-00-VP
7RecruitingSafety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults
Condition:Healthy Adult Immune Responses to Vaccine
Interventions:Biological: VRC-EBOADC069-00-VP;   Biological: VRC-EBOADC076-00-VP
8RecruitingSafety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults
Condition:Ebola Viruses
Interventions:Other: Placebo;   Biological: BPSC1001
9CompletedExperimental Ebola Vaccine Trial
Conditions:Hemorrhagic Fever, Ebola;   Healthy
Intervention:Drug: VRC-EBODNA012-00-VP
10Not yet recruitingA Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.
Condition:Ebola Virus Disease
Intervention:Biological: VSV-ZEBOV
11Not yet recruitingA Prospective, Open Label, Observational Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Infection Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Infection
Condition:Acute Ebola Virus Infection
Intervention:Biological: INTERCEPT Plasma
12RecruitingVSV-ZEBOV Geneva Vaccine Trial
Condition:Ebola Virus
Intervention:Biological: VSV-ZEBOV
13RecruitingVaccine Treatment for Ebola Virus in Healthy Adults
Condition:Ebola Virus
Interventions:Biological: BPSC-1001;   Other: Placebo
14Not yet recruitingAn Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
Condition:Ebola Virus
Intervention:Drug: CMX001
15RecruitingA Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland
Condition:Ebola Vaccines
Intervention:Biological: cAd3-EBOZ
16CompletedSafety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
Condition:Ebola Hemorrhagic Fever
Interventions:Drug: Placebo;   Drug: AVI-6002
17TerminatedSafety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion
Condition:Ebola Virus Infection
Interventions:Drug: TKM-100201;   Drug: Placebo
18WithdrawnA Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
Condition:Ebola Hemorrhagic Fever
Interventions:Drug: AVI-7537;   Other: Normal Saline Solution (NSS)
19SuspendedSafety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Condition:Ebola Virus Infection
Interventions:Drug: TKM-100802 for Injection;   Drug: Placebo
20CompletedPoly-ICLC to Prevent Respiratory Viral Infections A Safety Study
Conditions:Influenza;   Severe Acute Respiratory Distress Syndrome;   Smallpox;   Ebola;   Unknown Respiratory Viruses
Intervention:Drug: Poly-ICLC
21CompletedVRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
Condition:Healthy
Intervention:

http://clinicaltrials.gov/

参考文献

中新社华盛顿11月26日电(记者 刁海洋)美国国家卫生研究院(NIH)26日宣布,首个埃博拉疫苗成功通过临床试验,被证实安全有效。

这一成果当天发表在美国的一家医学杂志上。文章称,NIH下属的过敏与传染病研究院与葛兰素史克公司的研究人员从埃博拉病毒中提取出部分基因,并植入人体细胞内,最终制成疫苗。

http://news.sciencenet.cn/htmlnews/2014/11/308111.shtm

 

 



https://blog.sciencenet.cn/blog-280034-846709.html

上一篇:昌星,赖谁?
下一篇:见到林彪元帅的大女儿,真难得
收藏 IP: 106.39.222.*| 热度|

0

该博文允许注册用户评论 请点击登录 评论 (2 个评论)

数据加载中...
扫一扫,分享此博文

Archiver|手机版|科学网 ( 京ICP备07017567号-12 )

GMT+8, 2024-11-23 23:02

Powered by ScienceNet.cn

Copyright © 2007- 中国科学报社

返回顶部